These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38356670)

  • 1. Piperacillin‑tazobactam‑induced myocardial injury with heart failure: A case report.
    Liu Y; An C; Ai X; Zhang X; Shi L; Zhao Q
    Exp Ther Med; 2024 Mar; 27(3):105. PubMed ID: 38356670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.
    Perry CM; Markham A
    Drugs; 1999 May; 57(5):805-43. PubMed ID: 10353303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid-Onset Thrombocytopenia Following Piperacillin-Tazobactam Reexposure.
    Nguyen VD; Tourigny JF; Roy R; Brouillette D
    Pharmacotherapy; 2015 Dec; 35(12):e326-30. PubMed ID: 26684560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An unusual case of piperacillin-tazobactam-induced fever, eosinophilia, thrombocytopenia and liver damage.
    Lv J; Wu G; Zhang F; Su X
    Eur J Hosp Pharm; 2022 Mar; 29(e1):e91-e94. PubMed ID: 33558219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.
    Schoonover LL; Occhipinti DJ; Rodvold KA; Danziger LH
    Ann Pharmacother; 1995 May; 29(5):501-14. PubMed ID: 7655135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Piperacillin-Tazobactam-Induced Urticaria and Angioedema: A Case Report With Literature Review.
    Pandya S; Patel C; Sojitra B; Chaudhari N
    Cureus; 2024 Apr; 16(4):e58877. PubMed ID: 38800261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination.
    Gin A; Dilay L; Karlowsky JA; Walkty A; Rubinstein E; Zhanel GG
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):365-83. PubMed ID: 17547502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piperacillin/tazobactam versus imipenem: a double-blind, randomized formulary feasibility study at a major teaching hospital.
    Marra F; Reynolds R; Stiver G; Bryce E; Sleigh K; Frighetto L; MacDougall C; Jewesson P
    Diagn Microbiol Infect Dis; 1998 Jun; 31(2):355-68. PubMed ID: 9635910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematologic adverse effects induced by piperacillin-tazobactam: a systematic review of case reports.
    Wang Q; He Z; Wu X; Wei Y; Huang J
    Int J Clin Pharm; 2020 Aug; 42(4):1026-1035. PubMed ID: 32500262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of probable piperacillin/tazobactam-induced bone marrow suppression in a pregnant woman.
    ElSalem S; Elawad S; Ahmed A; AlSaadi M; AlHail M
    Eur J Hosp Pharm; 2019 May; 26(3):170-172. PubMed ID: 31428326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Piperacillin-Tazobactam Hypersensitivity: A Large, Multicenter Analysis.
    Casimir-Brown RS; Kennard L; Kayode OS; Siew LQC; Makris M; Tsilochristou O; Chytiroglou E; Nakonechna A; Rutkowski K; Mirakian R; Wagner A
    J Allergy Clin Immunol Pract; 2021 May; 9(5):2001-2009. PubMed ID: 33444815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(11):1135-75. PubMed ID: 11735679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of the in vitro activity of piperacillin/tazobactam.
    Daley D; Mulgrave L; Munro R; Neville S; Smith H; Dimech W
    Pathology; 1996 May; 28(2):167-72. PubMed ID: 8743825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piperacillin/tazobactam in the treatment of polymicrobial infections.
    Gorbach SL
    Intensive Care Med; 1994 Jul; 20 Suppl 3():S27-34. PubMed ID: 7962986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of severe intra-abdominal infections: the role of piperacillin/tazobactam.
    Nord CE
    Intensive Care Med; 1994 Jul; 20 Suppl 3():S35-8. PubMed ID: 7962987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.
    Réa-Neto A; Niederman M; Lobo SM; Schroeder E; Lee M; Kaniga K; Ketter N; Prokocimer P; Friedland I
    Curr Med Res Opin; 2008 Jul; 24(7):2113-26. PubMed ID: 18549664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
    Lister PD
    Pharmacotherapy; 2000 Sep; 20(9 Pt 2):213S-218S; discussion 224S-228S. PubMed ID: 11001328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-induced hypersensitivity syndrome related to piperacillin-tazobactam: a case report and review of the literature.
    Shen Y; Cui SS; Teng XB; Han MF
    Front Med (Lausanne); 2024; 11():1338247. PubMed ID: 38606160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Piperacillin-Tazobactam: a new beta-lactam-beta-lactamase inhibitor combination.
    Daniel KP; Krop LC
    Pharmacotherapy; 1996; 16(2):149-62. PubMed ID: 8820460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.